Paricalcitol
Paricalcitol (chemically it is 19-nor-1,25-(OH)2-vitamin D2. Marketed by Abbott Laboratories under the trade name Zemplar) is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic kidney failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2 (ergocalciferol).
It was patented in 1989 and approved for medical use in 1998.
Q306764
Abbott Laboratories
ORG
Q12140
drug
Concept
Q3622611
secondary hyperparathyroidism
Concept
Q202476
parathyroid hormone
Concept
Q736715
chronic kidney failure
Concept
Q485014
analog
Concept
Q139200
vitamin D2
Concept
Q155746
Paricalcitol
Concept
2020-01-25T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1,25
DATE
1989-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1989
DATE
1998-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
1998
DATE
+19^^http://www.w3.org/2001/XMLSchema#decimal
19
NUMBER
-1.25^^http://www.w3.org/2001/XMLSchema#decimal
-1,25
NUMBER
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
instance of
medical condition treated
medical condition treated